论文部分内容阅读
观察了30例伴微白蛋白尿或临床蛋白尿的NIDDM患者用Captopril或常规治疗4周后尿白蛋白及血浆过氧化脂质(LPO)水平的变化,结果表明,常规治疗后尿白蛋白无改变,而Captopril治疗后尿白蛋白减少,肾血浆流量增加,但尿白蛋白的减少与平均动脉压的降低无相关性。Captopril对肌酐清除率、血脂,血尿钾钠亦无明显影响。糖尿病患者血浆LPO水平高于健康对照者,Capropril治疗后降低,而常规治疗后无明显变化。以上结果提示,Captopril具有减少尿蛋白排泄及抗脂质过氧化作用。
30 cases of NIDDM patients with microalbuminuria or clinical proteinuria patients with Captopril or routine treatment for 4 weeks after urinary albumin and plasma lipid peroxidation (LPO) levels change, the results show that after conventional treatment of urinary albumin While Captopril decreased urinary albumin and increased renal plasma flow, but there was no correlation between reduction of urinary albumin and reduction of mean arterial pressure. Captopril on creatinine clearance, blood lipids, blood sodium and potassium also had no significant effect. Plasma LPO levels in diabetic patients were higher than those in healthy controls, decreased after Capropril treatment, and no significant changes after routine treatment. The above results suggest that Captopril can reduce urinary protein excretion and anti-lipid peroxidation.